white → red2
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
Not yet reviewed — this article is pending editorial review by Lyrea.
25iP-NBOMe
N-(2-Methoxybenzyl)-4-isopropyl-2,5-dimethoxyphenethylamine
2C-iP-NBOMe, NBOMe-2C-iP
25iP-NBOMe is a synthetic psychedelic of the substituted phenethylamine class, specifically an N-benzylated derivative of the hallucinogen 2C-iP. It has emerged as a rarely encountered novel designer drugcitation needed and remains largely unresearched. Reported to be extremely potent with stimulating qualities, it may produce uncomfortable body load and potentially dangerous vasoconstriction at higher doses. Very limited information is available regarding its safety profile and pharmacological properties.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~250 µg
Light300-750 µg
Moderate750-1000 µg
Strong1000-1500 µg
Heavy1500+ µg
Duration
Onset30-60 minutes
After Effects1-12 hours
Total5-7 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
25iP-NBOMe produces a stimulating psychedelic experience broadly typical of the NBOMe series, combining euphoria, empathy, and a sense of insight with prominent open and closed-eye visuals. The headspace involves a general shift in perception and a softening of the ego, though confusion can also occur. As with other N-benzylphenethylamines, the substance is active at sub-milligram doses and its subjective profile remains only sparsely documented.
Physical
The body experience carries a distinct stimulation with restlessness, muscle tension, and decreased appetite. Pupil dilation, sweating and chills, and difficulty sleeping are also reported.
Stimulation
Uncomfortable
Cognitive
The mental state is stimulating and euphoric, with enhanced empathy, a sense of insight, and a mild softening of the sense of self. Confusion is possible, particularly at stronger doses.
Emotional
Visual
Visual effects include brightened colors and both open and closed-eye visuals.
Tactile
Sense of touch is enhanced.
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
25iP-NBOMe produced off-target μ-opioid receptor activation in two cell-based assay systems, but the result was weak in the receptor-proximal β-arrestin-2 assay: about 6% of the hydromorphone reference response at 100 μM, without a plateau from which a reliable EC50 could be calculated.citation needed
Its apparently high response in the calcium-release assay was accompanied by the strongest non-MOR-mediated signal among the tested analogues, so that response cannot be treated as clean μ-opioid receptor efficacy.citation needed
Because μ-opioid activity in this series occurred only at high concentrations, the investigators considered clinically relevant opioid toxicity from this mechanism unlikely at physiologically relevant concentrations.1
Pharmacokinetics
Absorption & half-lifenot documented yetMetabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Cross Tolerance
Serotonergic psychedelics, 5-HT2A agonists
Harm Potential
Toxicity
Cardiovascular
May cause potentially dangerous vasoconstriction at high doses; the extreme potency of this compound increases the risk of accidental overdose leading to cardiovascular complications.
History & Culture
25iP-NBOMe emerged as a novel designer drug and was first documented in the scientific literature around 2014. Like other members of the NBOMe series, it represents an N-benzyl modification of an existing 2C-x compound—in this case, 2C-iP. The substance remains relatively obscure compared to more widely encountered NBOMe compounds such as 25I-NBOMe or 25C-NBOMe,citation needed with limited information available regarding its history of human use or cultural significance.
Legality
International
The 2025 Green List separately lists 25I-NBOMe in 1971 Convention Schedule I as 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine. That is not 25iP-NBOMe and does not establish structural coverage of 25iP-NBOMe. Complete current 1961, 1971, and 1988 INCB lists were inspected before reaching this absence finding.
By Country
Illegal4
CanadaIllegalControlled Drugs and Substances Act, Schedule III, item 352
25iP-NBOMe falls within Schedule III item 35's structural definition for 2C-phenethylamines. The definition covers a 2,5-dialkoxy phenethylamine with further benzene-ring substitution and an amino-group benzyl substitution, which encompasses the 2C-iP-NBOMe structure.
GermanyIllegal (analog/blanket ban)25iP-NBOMe is covered as a derivative of 2-phenethylamine under Annex 1 no. 1 of the NpSG: its substituted phenyl ring and N-(2-methoxybenzyl) group fit the listed modular structure. The NpSG defines a substance in an Annex 1 group as a new psychoactive substance and prohibits its manufacture, trade, supply, import/export, acquisition, possession, and administration, subject to stated exceptions.
UkraineIllegal25IP-NBOMe (2C-IP-NBOMe) is expressly listed in Table I, List No. 2 of Ukraine’s controlled-substances list, together with its chemical name. List No. 2 is headed ‘Especially dangerous psychotropic substances, circulation of which is prohibited,’ so the substance’s circulation is prohibited. Resolution No. 600 adds this entry to List No. 2; the amendment takes effect on 23 July 2019 and remains present in the current consolidated list.
United KingdomIllegalMisuse of Drugs Act 1971, Schedule 2, Part I, paragraph 1(f), as inserted by the Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 20148910
Controlled under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause, which covers NBOMe compounds as a structural class.11 Class A substances carry the most severe penalties, with possession punishable by up to 7 years imprisonment and supply by up to life imprisonment.10
References
Source Pages
Citations
- Deventer MH, Persson M, Laus A, Pottie E, Cannaert A, Tocco G, Gréen H, & Stove CP. (2023). Off-target activity of NBOMes and NBOMe analogs at the μ opioid receptor. Archives of Toxicology, 97(5), 1367–1384. https://doi.org/10.1007/s00204-023-03465-91
- Controlled Drugs and Substances Act, Schedule III, item 35. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/c-38.8/page-11.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 2. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__2.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 3. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
- Cabinet of Ministers Resolution No. 770: List of narcotic drugs, psychotropic substances and precursors, Table I, List No. 2. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/laws/show/770-2000-%D0%BF1
- Cabinet of Ministers Resolution No. 600 of 10 July 2019: amendments to the List of narcotic drugs, psychotropic substances and precursors. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/laws/show/600-2019-%D0%BF1
- Misuse of Drugs Act 1971, Schedule 2, Part I, paragraph 1(f), as inserted by the Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2014/11061
- Misuse of Drugs Act 1971, Schedule 2, Part I, paragraph 1(f), as inserted by the Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
- Misuse of Drugs Act 1971 — Schedule 4 (Prosecution and Punishment of Offences). legislation.gov.uk (1971). https://www.legislation.gov.uk/ukpga/1971/38/schedule/412
Further Reading
Ettrup A et al. 'Structure-Activity Relationships of NBOMe 5-HT2A Agonists' Journal of Neurochemistry 2013- King LA 'New phenethylamines in Europe' Drug Testing and Analysis 2014
- Nichols DE 'Psychedelics' Pharmacological Reviews 2016
Nichols DE. ‘Psychedelics’ Pharmacol Rev 2016 (general NBOMe toxicity)- Poulie CBM et al. 'Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability' Neurochemical Research 2014
- Rickli A et al. 'Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)' Neuropharmacology 2015
- Zawilska JB, Kacela M, Adamowicz P 'NBOMes–Highly Potent and Toxic Alternatives of LSD' Frontiers in Neuroscience 2020
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25iP-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.